

Global burden of neuroendocrine tumors and changing incidence in Kentucky

Aman Chauhan^{1,2}, Qian Yu¹, Neha Ray³, Zainab Farooqui⁴, Bin Huang^{1,5}, Eric B. Durbin^{1,2}, Thomas Tucker^{1,6}, Mark Evers^{1,7}, Susanne Arnold^{1,2} and Lowell B. Anthony^{1,2}

¹Markey Cancer Center, University of Kentucky, Lexington, KY, USA

²Department of Internal Medicine, University of Kentucky, Lexington, KY, USA

³University of Cincinnati School of Medicine, Cincinnati, Ohio, USA

⁴Kentucky College of Osteopathic Medicine, Pikeville, KY, USA

⁵Department of Biostatistics, University of Kentucky, Lexington, KY, USA

⁶Kentucky Cancer Registry, Lexington, KY, USA

⁷Department of Surgery University of Kentucky, Lexington, KY, USA

Correspondence to: Aman Chauhan, **email:** Amanchauhan@uky.edu

Keywords: neuroendocrine tumor incidence; kentucky cancer registry; SEER

Received: January 10, 2018

Accepted: March 15, 2018

Published: April 10, 2018

Copyright: Chauhan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Background: Neuroendocrine tumors (NETs) have a low incidence but relatively high prevalence. Over the last three decades, the incidence of NETs has risen 6-fold in the United States. We conducted an observational study to compare the incidence of NETs reported to the Kentucky Cancer Registry (KCR) versus that reported to Surveillance, Epidemiology, and End Results Program (SEER). We also provide a systematic review of the state of neuroendocrine tumors worldwide, and compare the available global and local published data.

Methods: KCR and SEER databases were queried for NET cases between 1995 and 2015. A detailed literature review of epidemiological data for various nations worldwide summarize epidemiological data from various countries.

Results: KCR recorded 6179 individuals with newly diagnosed NETs between 1995 and 2015. Between 1995-2012, the incidence of NETs in KCR increased from 3.1 to 7.1 per 100,000 cases, while it increased from 3.96 to 6.61 in the SEER database. The incidence rates in both KCR and SEER databases were linear. 90.57% were Caucasians with 54.74% females. 27.67% of the Kentucky population was from the Appalachian region. Patients aged 50-64 years had the highest prevalence (38%). Lung NET (30.60%) formed the bulk of cases, followed by small intestine (16.82%), rectum/anus (11.35%) and colon (9.71%).

Conclusions: NETs incidence between 1995 and 2015 show a linear increase in both KCR and SEER databases. Because of this increased incidence it is imperative for community oncologists to familiarize themselves with this entity, which until recently was under-studied and with few viable treatment options.

INTRODUCTION

Neuroendocrine tumors are frequently grouped with other rare malignancies, which limits drug development and clinical trial expansion for this important oncologic entity. Fortunately, the last 15 years have seen rapid changes in awareness and perception of general oncologists toward neuroendocrine tumors. As a result, there is not only an expansion of evidence-based standard of care data for the treatment of these patients, but future therapeutic drug developmental avenues also look promising. Robust epidemiological surveillance of this population helps us recognize the quantum of disease burden and unique patterns of disease presentation, which are key in the use of effective screening, targeted diagnostics, and treatments.

We performed a retrospective analysis of the Kentucky Cancer registry (KCR) and the Surveillance, Epidemiology, and End Results Program (SEER) databases between 1995 and 2015. Studies outside of the U.S. were also analyzed in terms of incidence, anatomical sites, grade, and survival. The aim of the study is to analyze epidemiologic and demographic data of newly diagnosed neuroendocrine tumors in Kentucky and compare this information with currently available global data.

RESULTS

We identified 6179 individuals with newly diagnosed NET between 2005 and 2015. We observed a steady rise in annual incidence of NET from 119 new cases in 1995 to 528 cases in 2015 (Table 1). After accounting for Kentucky's population increase (from 4.183 million to 4.425 million during those years), we determined that the corresponding incidence rate increased from 3.1 to 10.3 per 100,000 population (Table 1). Of our study patients, 90.57% were Caucasian with 54.74% females. Patients aged 50-64 years had the highest prevalence (38%). Geographically, 27.67% of our Kentucky population was from the Appalachian region. Lung NET (30.60%) formed the bulk of cases, followed by small intestine (16.82%), rectum/anus (11.35%) and colon (9.71%) (Table 2A). 46.92% of females presented with localized disease as compared to 36.07% males. 26.45% of African Americans NET patients were aged between 20-49 years as compared to 18.22% of Caucasian patients. Lung NET was highest among smokers, whereas small bowel NET was highest among nonsmokers.

The majority of cases (52%) were low grade, with 22% high grade, 3% intermediate grade, and the rest unknown (Table 2B). Grading of tumors is based on the globally-accepted WHO criteria, which considers Ki 67 <2% low grade, 2-20% intermediate grade, >20% high grade [1]. This grading system might be modified in the future based on recent data from Tang et al. [2] It should be

noted that roughly 25% of newly diagnosed NET patients are histologically placed at either G2 or G3. These patients have a distinct clinicopathological course as compared to low grade (G1) NETs.

Unlike most other malignancies, NETs are usually diagnosed at an early stage. In our study population, 42% had local disease at the time of diagnosis, 22% had loco-regional disease, 22% presented with distant metastatic disease, and the other 14% had an unknown status. Except for those with local disease, where 25% were females as compared to 16% males, the loco-regional and metastatic subgroups did not show any gender discrepancy. Staging has a profound impact on the choice of treatment, with early stage being curative with surgical resection alone, especially for low grade histology. As expected, 52% of our study population underwent surgery alone as the treatment of choice.

As far as age stratification is concerned, peak incidence was found in 50-64 year age group (38%), followed by 65-74 (25%), 20-49 (19%) and 75+ (18%). These data are in agreement with most found in the published literature.

Lastly, 27% of our study population reside in the Appalachian region. Multivariate analysis of the Appalachian population did not show significant aberration in patterns compared with the non-Appalachian population with regard to any of the previously discussed study variables.

DISCUSSION

Derived from the neural crest cells during development, NETs can arise from various primary sites in the body. Neuroendocrine tumors are commonly found in the gastrointestinal tract but it is not unusual to find neuroendocrine tumors in lungs, pancreas, thyroid, gonads, and other locations [3-5]. Besides site of origin, NETs can also be subdivided between secretory or non-secretory subgroups based on production of hormones or into high grade, intermediate grade or low-grade tumors based on the pathology. There is substantial heterogeneity among all these subgroups in terms of natural history of disease progression, response to therapeutic agents, and overall survival. Despite their low incidence rate, all NETs harbor the potential for malignancy, rendering the term "carcinoid tumor," adopted by previous researchers, inaccurate. In addition to their misnomer, the diagnosis criteria and classifications of NETs have been under debate since their discovery at the beginning of the last century. JACC, WHO, and ENETS criteria standards differ among each other, and the criteria for NETs from various sites may also vary within the same guideline. Along with the lack of population-based NET registries across the world in general, these variances have prevented us from elucidating the worldwide epidemiology of NETs over time. Rather, a multitude of studies emerged to assess

Table 1: KCR and SEER NETs cases, 2005-2015

Year	KCR (age adjusted incidence)	SEER (age adjusted incidence)	KCR (Cases)	SEER (Cases)
1995	3.1	3.96	119	1299
1996	3.6	4.12	138	1372
1997	3.6	4.29	141	1456
1998	4.7	4.73	188	1631
1999	5	4.76	204	1671
2000	5.3	4.9	218	3613
2001	5.2	4.67	214	3510
2002	5.5	5.14	232	3947
2003	5.2	5.29	226	4123
2004	5.9	5.44	257	4335
2005	5.8	5.56	257	4378
2006	6.3	5.94	281	4880
2007	7.4	6.16	342	5196
2008	7.4	6.27	351	5401
2009	7.2	6.38	346	5628
2010	8.2	6.57	405	5913
2011	7.1	6.61	351	6042
2012	8.4		414	
2013	8.6		447	
2014	10.4		520	
2015	10.3		528	

Table 2A: Site-specific prevalence of neuroendocrine tumors in Kentucky

Site	Prevalence (%)
Lung	30.6
Small Intestine	16.82
Rectum/Anus	11.35
Colon	9.71
Pancreas	5.5
Others	12.91
Unknown	7.61

Table 2B: Grade specific distribution of NETs in Kentucky

WHO 2010 Grading	%
G1	52
G2	3
G3	22
Unknown	23

the prognostic value of each classification scheme. In this systematic review, we examined NET cohort studies by country, focusing on the profile of NET composition and incidences, to gain a worldwide perspective of NET epidemiology.

Primary sites

Consistent with the SEER database, the most common NET sites in KCR database were lung, small intestine, and rectum-anus (Table 2A) [6]. A nation-wide study from Netherland also reported pulmonary NET being the most prevalent. In contrast, two studies from Denmark and Sweden reported small intestine NETs to be most prevalent [7, 8]. If only gastroenteropancreatic neuroendocrine tumors (GEP-NETs) were considered, studies in Argentina, France, and Norway reported the small intestine as being the most common anatomical location [9–11]. Table 3 summaries the three most prevalent NET sites globally. Appendix NET was prevalent among Western countries in general, which could be explained by accidental findings during appendectomy. The survival rates of appendix NET were also the most optimal, which might also result from early detections (Table 4). In contrast, rectal NET was particularly common in Asian populations [12–15]. Whether these distinctions resulted from genetic variations needs further research.

Grading and survival

From a global perspective, few countries reported grading data according to Ki-67 and/or mitotic counts due to the continuously evolving grading systems. The percentages of each grade varied among studies. Although a nation-wide, multicenter study in Korea reported a high G1 percentage of 92.3%, a regional study in China indicated that 73.9% of all graded cases were G3. Nevertheless, a consistent impression among all studies was that lower grade NETs demonstrated a better outcome in terms of survival. Tables 4 and 5 summarize global NET 5-year overall survival by site and by grade. Grade 1, Grade 2, and Grade 3 in our Kentucky population were 67.5%, 28.6%, and 3.9%, respectively (Table 2B). Table 6 summarizes global prevalence of NETs by grade. Our data underscores the fact that roughly 25% of newly diagnosed

NET patients in Kentucky present with either G2 or G3 histology. This is a significant number considering these intermediate grade and high grade NETs are often aggressive and have very limited treatment options.

Incidence

Unlike most malignancies, NET incidence has shown a constant incline. The cause of this increase is not entirely clear but experts have attributed the pattern to an increased awareness and improved diagnostics. The hike in incidence of this otherwise rare tumor has alerted public health stakeholders, which has resulted in establishment of specialized NET registries worldwide [16, 17]. A seminal paper from Yao et al. showed a 5-fold increase in incidence of NET from 1973 to 2004 [3]. Incidence of NET per Yao's report is estimated to be 5.25 cases per 100,000 population. Similar observations were made by Tsikitis et al. in the GI NET subgroup [18]. Per their report, overall incidence of GI NETs increased in all sites except for appendix tumors. In Germany, the age-standardized incidence increased from 2.7 to 3.4 fold from 1976 to 2006 [19]. In Italy, the incidence increased from 0.7 to 5.3 between 1976 and 2010 [20]. Based on recently published papers, increasing trends were also observed in China Japan, Korea, Norway, Netherlands, and Taiwan [11-15, 21]. Outside of the United States, incidence rates ranged from 1.41 to 5.86 based on studies published after 2000 [13, 15, 19, 20, 22-25]. Based on our analysis, the incidence of NETs reported in Kentucky according to the KCR database increased from 3.1 (1995) to 10.3 (2015) per 100,000 cases. In contrast, according to SEER data, the incidence increased from 3.9 to 6.61 between 1995 and 2012 (Figure 1).

Limitations

Since the beginning of the last century, the nomenclature, diagnostic criteria and classification of NETs have been evolving. "Carcinoid tumor", a previous term adopted by several early studies, was inaccurate because all NETs harbor the potential for malignancy [7, 26–30]. Older versions of the International Classification of Disease for Oncology excluded benign NETs. The WHO has changed grading criteria over time. All of these inconsistencies prevent achieving a clear comparison of

Table 3: Top 3 primary sites of NETs, reported by country

Country	Authors	Years	Sample size	1 st Most Common Primary Site	2 nd Most Common Primary Site	3 rd Most Common Primary Site
Argentina	[9]	NA	532 (GEP-NET only)	Small Intestine (26.9%) ¹	Pancreas (25.2%)	Colon-Rectum-Anus (12.4%)
Austria (prospective study)	[22]	2004-2005	265	Stomach (23%)	Appendix (21%)	Small Intestine (15%)
Brazil	[31]	1997-2009	773 (GEP-NET only)	Stomach (24.5%)	Small Intestine (20.8%)	Rectum (20.5%)
Canada	[23]	1994-2009	5619	Pancreas (25%)	Colon (22.8%)	Small Intestine (21.6%)
Canada	[25]	1990-2005	530	Small Intestine (55.3%)	Colon (18.3%)	Appendix (17.9%)
China	[13]	2009-2013	248 (GEP-NET only)	Rectum (30.6%)	Pancreas (23.4%)	Gastric (13.3%)
China	[32]	1991-2013	130 (NET with liver metastasis only)	Pancreas (65.4%)	Stomach (10.8%)	Small Intestine (5.4%)
China	[33]	2011-2016	440 (GEP-NET only)	Stomach (24.3%)	Rectum (24.1%)	Pancreas (20.5%)
China (Hongkong)	[34]	1994-2013	126 (GEP-NET only)	Pancreas (34.9%)	Rectum (33.3%)	Stomach (8.7%)
Denmark	[7]	1978-1989	1029	Small Intestine (29.4%)	Appendix (17.9%)	Pulmonary (16.8%)
France	[10]	2001-2002	668 (GEP-NET only)	Small Bowel and Colon (43%)	Pancreas (32%)	Gastric (5%)
Germany	[35]	2004-2007	1263	Pancreas (31%)	Small Intestines (22%)	Colon and Rectum (11.4%)
Italy	[36]	2004-2007	1203	Pancreas (31%)	Lung (29%)	Ileum, Cecum, Colon, Rectum (13%)
Korea	[14]	2000-2009	4951 (GEP-NET only)	Rectum (48%)	Stomach (14.6%),	Colon (7.9%)
Lebanon	[37]	2001-2012	89 (GEP-NET)	Pancreas (24.7%)	Stomach (20.8%)	Duodenum (18.2%)
Mexico	[38]	NA	495 (GEP-NET only)	Pancreas (33.27%)	Stomach (28.02%)	NA
Norway	[24]	1993-2004	2030	Small Intestine (25.5%)	Lung and Bronchus (21%)	Colon (8%)
Norway	[11]	2003-2013	204 (GEP-NET only)	Small Intestines (29.4%)	Appendix (23.5%)	Pancreas (16.2%)
Netherlands	[21]	2001-2010	24759	Pulmonary (72.7%)	Appendix (3.9%)	Small Intestine (3.7%)
Spain	[39]	2001-2008	907	Pancreas (34%)	Jejunum-Ileum (15.6%)	Appendix (9.4%)
Sweden	[8]	1987-2012	7334	Small Intestine (32%)	Appendix (23%)	Lung (15%)
Taiwan	[15]	1996-2008	2187	Rectum (25.4%)	Lung/Bronchus (20%)	Stomach (7.4%)
United States (by incidence)	[6]	2000-2012	64971	Lung (1.49%)	Small Intestine (1.05%)	Rectum (1.04%)

¹Values in parentheses are % of study cohort.

Table 4: Five-year overall survival (OS) rate of NET by primary site (%)

Country	Authors	Rectum	Lung	Stomach	Pancreas	Colon	Small Intestine	Appendix
Canada	[25]	100		70		73	70	84
Germany	[19]	50		53	52	48	68	86
Norway	[24]	74	54	45	43	41	59	74
Spain	[39]	64.1		61.4	78.1	65.1	Duodenum (89.3), Jejunum-Ileum (83.0)	100
Taiwan	[21]	80.9	33.9	46.4	30.2	48.1	47.9	75.7
U.S. (Distant stage G1/G2 only; diagnosed from 2000-2012)	[6]	28	32	32	50	29	69	
U.S. (reported by median OS time in years)	[6]	24.6	5.5		3.6			>30

Table 5: Five-year OS rate of NET by grade (%)

Country	Authors	G1	G2	G3
Argentina (GEP-NET only; values were estimated from graph)	[9]	>75	50-75	<25
China (NET with liver metastasis only)	[32]	55.6 (surgical resected patients); 14.3 (non-surgically resected patients)	35.3 (surgical resected patients); 0 (non-surgically resected patients)	28.6 (surgical resected patients); 0 (non-surgically resected patients)
Korea (GEP-NET only)	[14]	94.2	70.38	42.96
Netherlands (based on the data from 2001-2010)	[21]	80	63	20 (G3-LCNEC), 6 (G3-SCNEC)
Spain (GEP-NET only)	[39]	83.3	77.1	43.5
U.S. (reported by median OS time)	[6]	16.2 years	8.3 years	10 months (including G4)

Table 6: Percentages of NET subtypes categorized according to WHO2010 criteria, reported by country

Country	Author	G1	G2	G3	Others (if applicable)
Argentina (GEP-NET only)	[9]	29.5%	35.9%	9.0%	No data (25.6%)
Brazil	[31]	73.2%	10.5%	16.3%	
China	[13]	3.1%	18.0%	73.9%	MANEC (9.1%)
China	[32]	27.3%	51.5%	21.2%	
China	[33]	29.5%	27.3%	43.2%	
China (Hong Kong)	[34]	87.3%	NA	NA	
Germany	[35]	40.4%	51.1%	18.4%	
Korea	[14]	92.31%	4.85%	2.84%	
Lebanon	[37]	56.2%	11.2%,	20.2%,	MANEC (12.4%)
Mexico	[38]	64%	13%	23%	
Netherlands	[21]	17%	1%	G3-LCNEC (7%) G3-SCNEC (75%)	
Norway	[11]	53.4%	24.0%	19.6%	
Spain	[39]	44.4%	37.8%	17.8%	
U.S.	[6]	51.0%	16.4%	32.5% (including G4)	




Figure 1: NET incidence according to KCK (blue/series 1) and SEER (red/series 2) [6].

different epidemiology studies overtime. Most countries do not have a nation-wide, population based NET registries. Single-center or regional studies cannot assess national incidence and prevalence convincingly.

MATERIALS AND METHODS

KCR is a part of NCI's SEER program and has been collecting population-based cancer data since 1986. We sought Institutional Review Board approval prior to commencement of our study, then proceeded to review the KCR and SEER databases for all newly diagnosed neuroendocrine tumors in Kentucky between 1995 and 2015. Incidence data were adjusted for population. Multivariate analysis was performed using SPSS to analyze various demographic and disease-specific study variables. Tumors were characterized by primary sites. Grading was based on the globally-accepted WHO criteria, which considers Ki 67 <2% low grade (G1), 2-20% intermediate grade (G2), >20% high grade (G3) [1].

Studies outside of the United States (U.S.) were reviewed according to search results from PubMed and Google Scholar. Examples of key words included: "neuroendocrine+tumor"; "neuroendocrine+neoplasm"; "neuroendocrine+prevalence"; "neuroendocrine+incidence"; "neuroendocrine+burden"; "neuroendocrine+epidemiology"; "carcinoid+tumor"; "carcinoid+incidence. Studies were sorted into tables according to authors, date, sample size, primary sites of tumor, grading, survival. Re-calculations were performed in some cases based on data from original studies in order to exclude unknown type and to obtain percentages of each tumor type and grade.

CONCLUSIONS

NETs incidence between 1995 and 2015 showed a linear increase in both KCR and SEER databases. NET incidence has undoubtedly increased over the past two decades. It is imperative for community oncologists to familiarize themselves with this entity, which until recently was under-studied and without many viable treatment options.

ACKNOWLEDGMENTS

This research was supported by the Cancer Research Informatics Shared Resource of the University of Kentucky Markey Cancer Center (P30CA177558). Authors would like to acknowledge Donna Gilbreath and Cathy Anthony for assistance in preparation of this manuscript.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Bosman FT. WHO classification of tumours of the digestive system. World Health Organization, International Agency for Research on Cancer. 2010.
2. Tang LH, Untch BR, Reidy DL, O'Reilly E, Dhall D, Jih L, Basturk O, Allen PJ, Klimstra DS. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: A pathway distinct from poorly differentiated neuroendocrine carcinomas. *Clin Cancer Res.* 2016; 22: 1011-1017.
3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *J Clin Oncol.* 2008; 26: 3063-3072.
4. Modlin IM, Champaneria MC, Chan AK, Kidd M. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: The rapid pace of no progress. *Am J Gastroenterol.* 2007; 102: 1464-1473.
5. Fraenkel M, Kim MK, Faggiano A, Valk GD. Epidemiology of gastroenteropancreatic neuroendocrine tumours. *Best Pract Res Clin Gastroenterol.* 2012; 26: 691-703.
6. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. *JAMA Oncol.* 2017; 3:1335-42.
7. Westergaard T, Frisch M, Melbye M. Carcinoid tumors in Denmark 1978–1989 and the risk of subsequent cancers. A population-based study. *Cancer.* 1995; 76: 106-109.
8. Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. *Int J Cancer.* 2016; 139: 2679-2686.
9. O'Connor JM, Marmissolle F, Bestani C, Pesce V, Belli S, Dominichini E, Mendez G, Price P, Giacomi N, Pairola A, Loria FS, Huertas E, Martin C, et al. Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study. *Mol Clin Oncol.* 2014; 2: 673-684.
10. Lombard-Bohas C, Mitry E, O'Toole D, Louvet C, Pillon D, Cadiot G, Borson-Chazot F, Aparicio T, Ducreux M, Lecomte T. Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. *Neuroendocrinology.* 2009; 89: 217-222.
11. Sandvik OM, Søreide K, Gudlaugsson E, Kvaløy JT, Søreide JA. Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria. *Br J Surg.* 2016; 103: 226-232.
12. Ito T, Igarashi H, Nakamura K, Sasano H, Okusaka T, Takano K, Komoto I, Tanaka M, Imamura M, Jensen RT. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. *J Gastroenterol.* 2015; 50: 58-64.

13. Guo LJ, Wang CH, Tang CW. Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution. *Asian Pac J Clin Oncol*. 2016; 12: 284-288.
14. Cho MY, Kim JM, Sohn JH, Kim MJ, Kim KM, Kim WH, Kim H, Kook MC, Park DY, Lee JH. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000-2009: multicenter study. *Cancer Res Treat*. 2012; 44: 157.
15. Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS. The epidemiology of neuroendocrine tumors in Taiwan: A nation-wide cancer registry-based study. *PLoS One*. 2013; 8: e62487.
16. Stefanov R, Miteva-Katrandjieva T, Iskrov G, Damyanov D, Korukov B, Kermedchiev M, Terziev I, Madjov R, Ivanov K, Kolev N, Chenopolski P, Tsaneva M, Dimitrova V, et al. Epidemiological registry of neuroendocrine tumors in Bulgaria--a pilot survey. *Khirurgiia (Sofia)*. 2014; 7-13.
17. van der Zwan JM, Trama A, Otter R, Larranaga N, Tavilla A, Marcos-Gragera R, Dei Tos AP, Baudin E, Poston G, Links T, Rarecare WG. Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project. *Eur J Cancer*. 2013; 49: 2565-2578.
18. Tsikitis VL, Wertheim BC, Guerrero MA. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. *J Cancer*. 2012; 3: 292-302.
19. Scherübl H, Streller B, Stabenow R, Herbst H, Höpfner M, Schwertner C, Steinberg J, Eick J, Ring W, Tiwari K. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. *World J Gastroenterol*. 2013; 19: 9012.
20. Fanello S, Mangone L, Sacchetti C, Vicentini M, Pinto C, and AIRTUM WORKING GROUP. Variety of hormones produced by rare neuroendocrine tumors (NETs): Examination of epidemiology and prognostic factors for NETs in Italy. *Journal of Clinical Oncology*. 2016; 34:e15656.
21. Korse CM, Taal BG, van Velthuysen ML, Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. *Eur J Cancer*. 2013; 49: 1975-1983.
22. Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: An analysis based on prospectively collected parameters. *Endocr Relat Cancer*. 2010; 17: 909-918.
23. Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes. *Cancer*. 2015; 121: 589-597.
24. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, Modlin IM. Neuroendocrine tumor epidemiology. *Cancer*. 2008; 113: 2655-2664.
25. McMullen T, Al-Jahdali A, de Gara C, Ghosh S, McEwan A, Schiller D. A population-based study of outcomes in patients with gastrointestinal neuroendocrine tumours. *Can J Surg*. 2017; 60: 192.
26. Berge T, Linell F. Carcinoid tumours. *APMIS*. 1976; 84: 322-330.
27. Godwin JD. Carcinoid tumors an analysis of 2837 cases. *Cancer*. 1975; 36: 560-569.
28. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors. *Cancer*. 2001; 92: 2204-2210.
29. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, Öberg K. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. *Ann Oncol*. 1997; 8: 685-690.
30. Newton J, Swerdlow A, dos Santos Silva I, Vessey M, Grahame-Smith D, Primatesta P, Reynolds D. The epidemiology of carcinoid tumours in England and Scotland. *Br J Cancer*. 1994; 70: 939.
31. Estrozi B, Bacchi CE. Neuroendocrine tumors involving the gastroenteropancreatic tract: A clinicopathological evaluation of 773 cases. *Clinics*. 2011; 66: 1671-1675.
32. Du S, Wang Z, Sang X, Lu X, Zheng Y, Xu H, Xu Y, Chi T, Zhao H, Wang W. Surgical resection improves the outcome of the patients with neuroendocrine tumor liver metastases: large data from Asia. *Medicine (Baltimore)*. 2015; 94:e388.
33. Zhang M, Zhao P, Shi X, Zhao A, Zhang L, Zhou L. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: A large, retrospective single-centre study. *BMC Endocr Disord*. 2017; 17: 39.
34. Chan DT, Luk AO, So W, Kong AP, Chow FC, Ma RC, Lo AW. Natural history and outcome in chinese patients with gastroenteropancreatic neuroendocrine tumours:-a 17-year retrospective analysis. *BMC Endocr Disord*. 2016; 16: 12.
35. Ploekinger U, Kloepfel G, Wiedenmann B, Lohmann R. The German NET-Registry: An audit on the diagnosis and therapy of neuroendocrine tumors. *Neuroendocrinology*. 2009; 90: 349-363.
36. Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davi M, Bianchi A, Valcavi R, Papini E, Giuffrida D. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. *J Endocrinol Invest*. 2012; 35: 817.
37. Kourie HR, Ghorra C, Rassy M, Kesserouani C, Kattan J. Digestive neuroendocrine tumor distribution and characteristics according to the 2010 WHO Classification: A single institution experience in lebanon. *Asian Pac J Cancer Prev*. 2016; 17: 2679-2681.

38. Medrano Guzman R. (2017). Clinical and epidemiological features in 495 gastroenteropancreatic neuroendocrine patients in Mexico. *Journal of Clinical Oncology*. 2017; 35:e15687.
39. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez J, Martínez Del Prado M, Alonso Orduna V,

Sevilla-Garcia I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Munoz M. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE). *Ann Oncol*. 2010; 21: 1794-1803.